Launch of the Montelukast Authorized Generic
First written in FY2017-Q1. 4 of 6 entries say "Cited as achieved", first in FY2017-Q3. Latest entry: FY2018.
No other company in this theme has enough history to compare yet.
- FY2018Cited as achievedAnnual report
「Sales of Montelukast Tablets 10 mg and 5 mg "KM," launched by キョーリン リメディオ㈱ in September 2016, increased substantially」
The launch of the authorized generic of montelukast is cited as evidence of subsequent growth in generic drug sales. - FY2018-Q2Cited as achievedAnnual report
「Montelukast Tablets 10 mg and 5 mg "KM," launched by キョーリン リメディオ㈱ in September 2016」
The launch of the authorized generic of montelukast is cited as evidence of subsequent growth in generic drug sales. - FY2017Cited as achievedAnnual report
「The company launched the authorized generic of montelukast during the fiscal year and began pursuing authorized generics as a group.」
The launch of the authorized generic of montelukast is cited as evidence that the group began its authorized generic business. - FY2017-Q3Cited as achievedAnnual report
「The bronchial asthma and allergic rhinitis treatment Montelukast Tablets 10 mg and 5 mg "KM," launched by キョーリン リメディオ㈱ in September 2016」
The launch of the authorized generic of montelukast in September 2016 is cited as evidence of subsequent sales growth. - FY2017-Q2AchievedAnnual report
「キョーリン リメディオ㈱ launched in September the bronchial asthma and allergic rhinitis treatment Montelukast Tablets 10 mg and 5 mg "KM," which was listed in the National Health Insurance drug price standard in June 2016.」
The company launched the authorized generic of montelukast, which had been scheduled for launch in September 2016. - FY2017-Q1First statedAnnual report
「The company plans to launch the product in early September.」
The planned launch of the montelukast authorized generic was set for early September 2016.